Umbrella Meta-Analysis of Fibrates for Primary Biliary Cholangitis Treatment

Twenty-three meta-analyses, encompassing 45 unique randomized controlled trials with 3,276 patients, were synthesized to evaluate fibrate therapy for primary biliary cholangitis. The analysis was conducted by Jian Zhang and published on figshare in 2026. It reports biochemical outcomes, treatment response rates, and adverse events for ursodeoxycholic acid and fibrate combination therapy.

Use Cases

• Compare biochemical response rates between monotherapy and combination therapy based on reported risk ratios.
• Assess the safety profile of fibrates in PBC based on reported adverse event rates.
• Evaluate the methodological quality and overlap of existing meta-analyses in this clinical domain.
• Inform clinical guideline development for primary biliary cholangitis treatment based on synthesized evidence.

Strengths

• Synthesizes evidence from 23 meta-analyses and 45 unique RCTs, providing a high-level overview.
• Reports specific quantitative findings, such as a mean difference in ALP of -85.4 U/L for combination therapy.
• Assesses methodological quality using AMSTAR 2 and overlap using corrected covered area (CCA=11%).
• Includes data on 3,276 patients after removing duplicate RCTs across meta-analyses.

Limitations

• The dataset is a 15.3 KB DOCX file containing a manuscript, not a structured data table; column-level documentation is absent.
• Evidence on survival and transplant-free outcomes is noted as insufficient.
• Row count for any underlying data is unknown, limiting suitability assessment for direct analysis.

Provenance

Source

figshare

Collection Method

Systematic review and umbrella meta-analysis of published meta-analyses and randomized controlled trials.

Time Range

Meta-analyses searched from database inception to 2025.

Freshness

Last updated 2026-05-25 04:33:18.